The Future of Lung Cancer Screening: Implementing, Expanding, and Innovating

All of the relevant financial relationships listed for these individuals have been mitigated. Unless otherwise noted, speakers have nothing to disclose.

Moderators

Chi-Fu Jeffrey Yang, MD
Disclosure(s): AstraZeneca: Advisory Board (Ongoing); Genentech: Advisory Board (Ongoing)

Ammara A. Watkins, MD, MPH

Presentations

  1. Expanding Eligibility Criteria for Lung Cancer Screening: Pro
    Douglas E. Wood, MD, FACS, FRCSEd
     
  2. Expanding Eligibility Criteria for Lung Cancer Screening: Con
    Chris Slatore, MD, MS
     
  3. Discussion
     
  4. After Screening Surgical Follow Up
    Cherie Erkmen, MD
    Disclosure(s): AstraZeneca; BMS; Merck; Roche/Genentech: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Pfizer, USA: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)
     
  5. Incidental Nodules vs. Screen-Detected Nodules: Is There a Difference?
    Neel Chudgar, MD
    Disclosure(s): AstraZeneca: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); LUNGevity: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)
     
  6. Lung Cancer and Lung Cancer Screening in Individuals Without a Smoking History
    Natalie Lui, MD
    Disclosure(s): Centese: Sponsored research agreement (Terminated, June 30, 2024); Intuitive Foundation: Research grant (Terminated, June 30, 2024); Intuitive Surgical: Consultant (Ongoing)
     
  7. Discussion
     
  8. Reassessing Efficacy: Understanding Failures in Lung Cancer Screening Despite Low-Dose CT Protocol Adherence
    Victoria Shiqi Wu
     
  9. The Harms of Lung Cancer Screening: Telling Truths and Dispelling Myths
    Hari B. Keshava, MD MS FACS
    Disclosure(s): AstraZeneca (Any division): Consultant (Ongoing), Speaker (Ongoing)
     
  10. Novel Adjuncts to Lung Cancer Screening to Expand Screening Eligibility and Reduce Screening Harms
    Jane Yanagawa, MD
    Disclosure(s): AstraZeneca: Advisory Board (Ongoing), Steering Committee Member (Ongoing); OncLive: Lung Cancer Workshop Attendee (Ongoing)
     
  11. Discussion
     
  12. Achieving Equitable Care for Underrepresented Minority Patients with a Lung Cancer Screening Program
    Azante Griffith
Activity summary
Available credit: 
  • 1.75 ABS Accredited CME
  • 1.75 ABTS Accredited CME
  • 1.75 AMA PRA Category 1 Credit
Activity opens: 
03/01/2025
Activity expires: 
03/01/2028
Cost:
$0.00
Rating: 
0

Available Credit

  • 1.75 ABS Accredited CME
  • 1.75 ABTS Accredited CME
  • 1.75 AMA PRA Category 1 Credit

Price

Cost:
$0.00
Please login or register to take this course.

All of the relevant financial relationships listed for these individuals have been mitigated. Unless otherwise noted, speakers have nothing to disclose.

Moderators

Chi-Fu Jeffrey Yang, MD
Disclosure(s): AstraZeneca: Advisory Board (Ongoing); Genentech: Advisory Board (Ongoing)

Ammara A. Watkins, MD, MPH

Presentations

  1. Expanding Eligibility Criteria for Lung Cancer Screening: Pro
    Douglas E. Wood, MD, FACS, FRCSEd
     
  2. Expanding Eligibility Criteria for Lung Cancer Screening: Con
    Chris Slatore, MD, MS
     
  3. Discussion
     
  4. After Screening Surgical Follow Up
    Cherie Erkmen, MD
    Disclosure(s): AstraZeneca; BMS; Merck; Roche/Genentech: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Pfizer, USA: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)
     
  5. Incidental Nodules vs. Screen-Detected Nodules: Is There a Difference?
    Neel Chudgar, MD
    Disclosure(s): AstraZeneca: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); LUNGevity: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)
     
  6. Lung Cancer and Lung Cancer Screening in Individuals Without a Smoking History
    Natalie Lui, MD
    Disclosure(s): Centese: Sponsored research agreement (Terminated, June 30, 2024); Intuitive Foundation: Research grant (Terminated, June 30, 2024); Intuitive Surgical: Consultant (Ongoing)
     
  7. Discussion
     
  8. Reassessing Efficacy: Understanding Failures in Lung Cancer Screening Despite Low-Dose CT Protocol Adherence
    Victoria Shiqi Wu
     
  9. The Harms of Lung Cancer Screening: Telling Truths and Dispelling Myths
    Hari B. Keshava, MD MS FACS
    Disclosure(s): AstraZeneca (Any division): Consultant (Ongoing), Speaker (Ongoing)
     
  10. Novel Adjuncts to Lung Cancer Screening to Expand Screening Eligibility and Reduce Screening Harms
    Jane Yanagawa, MD
    Disclosure(s): AstraZeneca: Advisory Board (Ongoing), Steering Committee Member (Ongoing); OncLive: Lung Cancer Workshop Attendee (Ongoing)
     
  11. Discussion
     
  12. Achieving Equitable Care for Underrepresented Minority Patients with a Lung Cancer Screening Program
    Azante Griffith